Every GLP-1 coupon and savings card, with the catch attached
Every GLP-1 savings program below is printed with the condition that ends it. Each entry carries who qualifies, what the offer actually costs, the catch in plain words, and the date it expires. Each drug also has its own page, with the offer set against what it costs when no card applies.
Dated offers
- Ozempic and Wegovy cash price via GoodRx — $199 a month for the first two fills at 0.25 mg and 0.5 mg, then $349. Ends 2026-03-31 — already expired, treat any quote of it as stale.
- Mounjaro Savings Card — As little as $25 for a 1-, 2- or 3-month fill. Ends 2026-12-31 (88 days).
- Trulicity Savings Card — As little as $25 for a 1-, 2- or 3-month fill. Ends 2026-12-31 (88 days).
- Zepbound savings card — As little as $25 for up to a 3-month prescription. Ends 2026-12-31 (88 days).
- Ozempic first-fill price — $199 a month for the first two fills at 0.25 mg or 0.5 mg. Ends 2026-12-31 (88 days).
- Wegovy first-fill price — $199 a month for 0.25 mg and 0.5 mg. Ends 2026-12-31 (88 days).
- Medicare GLP-1 Bridge — $50 a month. Ends 2027-12-31 (453 days).
$199 a month for the first two fills at 0.25 mg and 0.5 mg, then $349
- Who for
- Cash-paying patients using GoodRx on Ozempic or Wegovy for the first time
- The catch
- GoodRx's own announcement ends the footnote with "Offer valid through March 31, 2026", so the price has an expiry the headline never carried. It covered two fills at the two lowest doses only; after them the price is $349 a month, and Ozempic 2.0 mg was never in it at all — that stayed $499. Using Ozempic for weight loss without type 2 diabetes is off-label.
- Ends
- 2026-03-31 — ended; no longer available
sourcechecked 2026-09-05As little as $25 for a 1-, 2- or 3-month fill
- Who for
- Commercially insured with coverage for Mounjaro; barred for Medicare, Medicaid and any federal program
- The catch
- Capped at $150 of savings a month and $1,950 a year. Without coverage the same card lets you pay as little as $499 for a 28-day fill, with Lilly's savings in that case capped at $647 a month and $8,411 a year.
- Ends
- 2026-12-31
sourcechecked 2026-09-05As little as $25 for a 1-, 2- or 3-month fill
- Who for
- Commercial drug insurance that covers Trulicity, and a prescription for an FDA-approved use. Lilly's own terms put it plainly: governmental beneficiaries excluded.
- The catch
- Capped at $150 of savings a month and $1,950 a calendar year, across at most 13 fills. Those two ceilings meet to the dollar — $150 across 13 fills is exactly $1,950 — so whichever limit you count against, the card is spent after one year of monthly fills. A month here is 28 days and up to 4 pens, which is why 13 fills is a year rather than 12.
- Ends
- 2026-12-31
sourcechecked 2026-09-08As little as $25 for up to a 3-month prescription
- Who for
- Commercially insured with coverage for Zepbound
- The catch
- The $25 needs a commercial plan that already covers the Zepbound single-dose pen. Without coverage the same card lets you pay as little as $499 for a 28-day fill of the single-dose pen, up to 13 fills a year, or for the KwikPen as little as $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up. Lilly's terms exclude anyone in a state, federal or government-funded program, and the list is longer than Medicare and Medicaid: Medicare Part D, Medicare Advantage, Medigap, DoD, VA and TRICARE are all named in it.
- Ends
- 2026-12-31
sourcechecked 2026-09-05$199 a month for the first two fills at 0.25 mg or 0.5 mg
- Who for
- New self-pay patients paying cash through TrumpRx
- The catch
- Two monthly fills only, between 17 November 2025 and 31 December 2026. Every fill after it is $349 a month at 0.25, 0.5 or 1 mg and $499 at 2 mg.
- Ends
- 2026-12-31
sourcechecked 2026-09-11$199 a month for 0.25 mg and 0.5 mg
- Who for
- New to the Wegovy savings offer or to NovoCare Pharmacy, paying cash
- The catch
- Two monthly fills only, and the offer itself closes on 31 December 2026. After either limit the price is $349.
- Ends
- 2026-12-31
sourcechecked 2026-09-05$50 a month
- Who for
- Part D beneficiaries 18 or older whose prescriber submits a prior authorization attesting the drug treats obesity, and who have a BMI of 35 or higher, a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension or stage 3a chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not for anyone with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or whose Part D plan already covers a GLP-1. Covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound only — not the single-dose Zepbound vials or pens.
- The catch
- The $50 does not count toward your Part D deductible or the out-of-pocket maximum, because the demonstration sits outside Part D coverage rather than inside it. It is also time-limited: a demonstration under Section 402 authority, not a benefit.
- Ends
- 2027-12-31
sourcechecked 2026-09-05$99 a month with free shipping
- Who for
- Anyone with a prescription, cash-paying
- Ends
- No published end date
sourcechecked 2026-09-12$149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at 9 mg, 14.5 mg and 17.2 mg
- Who for
- Self-pay through LillyDirect
- The catch
- The $299 at 14.5 mg and 17.2 mg holds only while you refill within 45 days; miss that and Lilly's regular price applies, which this page does not print. The $149 at 2.5 mg and the $199 at 5.5 mg are marked as temporarily reduced through 31 December 2026. A month here is 30 days.
- Ends
- No published end date
sourcechecked 2026-09-05$449 a month at 7.5 mg and above
- Who for
- Self-pay through LillyDirect
- The catch
- Only while you refill within 45 days. Lapse once and 10 mg and above cost $699 — and Lilly counts a month as 28 days, so a year is 13 fills.
- Ends
- No published end date
sourcechecked 2026-09-05As little as $25 a month
- Who for
- Commercial insurance that covers Ozempic. Government beneficiaries excluded, and Novo's page names Medicare Part D among them.
- The catch
- Capped at $100 of savings a month and good for up to 48 months, so it reaches $25 only where your plan already covers most of the cost — a $300 copay becomes $200. The same terms cover the pen and the Ozempic tablets. No annual ceiling and no end date are published.
- Ends
- No published end date
sourcechecked 2026-09-11As little as $25 for a 1-, 2- or 3-month prescription
- Who for
- Commercially insured patients with coverage for Rybelsus (Novo's wording: "Eligible, commercially insured patients with product coverage only").
- The catch
- Capped at $100 of savings for a 1-month supply, $200 for two and $300 for three — two-thirds of the $150 Lilly allows on its Mounjaro and Trulicity cards, and the same as its Zepbound card, for the same $25 headline. At 7 mg and 14 mg the prescription itself has to be written as a 1-, 2- or 3-month supply to qualify; at 3 mg the offer is $25 a month. No annual ceiling and no fill limit is published on this page, and no end date either, which means the terms can change without one expiring.
- Ends
- No published end date
sourcechecked 2026-09-08$149 a month at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg
- Who for
- Cash-paying patients on any oral dose, filled through NovoCare Pharmacy
- The catch
- The $149 covers only the 1.5 mg starting month. The 4 mg month is $199, and every month from 9 mg up, including the 25 mg maintenance dose, is $299. Novo Nordisk says it can change or cancel the pricing at any time.
- Ends
- No published end date
sourcechecked 2026-09-05As little as $25 a month
- Who for
- Commercial insurance that covers Wegovy. Government beneficiaries excluded.
- The catch
- Savings are capped at $100 a month, so it only reaches $25 if your plan already covers most of the cost.
- Ends
- No published end date
sourcechecked 2026-09-05$74.99 for a 30-day supply, or $210 for 90 days — $70 a month
- Who for
- Cash-paying patients ordering through Qsymia Engage home delivery, which processes no insurance claims
- The catch
- Shipping and handling is added to every order except the 90-day one, and 90-day prescriptions are not sold in every state. Qsymia is separately restricted under an FDA REMS, which means only certified pharmacies may dispense it; the label also asks for a negative pregnancy test before starting and every month after, in anyone who can become pregnant.
- Ends
- No published end date
sourcechecked 2026-09-05
By drug
Each of these sets its programs against the drug's own verified price, what a pharmacy pays for it, and what a year of it comes to.
What these cards actually cap
The advertised $25 is a copay, not a price, and every card caps what the manufacturer contributes per fill; 3 of the 6 also cap it per calendar year, and the rest publish no annual ceiling. Lilly's Zepbound ceilings meet exactly at its fill limit, so the card covers one year and not one refill more. The figure still in widest circulation for it is the ceiling Lilly cut in January.
Every published ceiling, the arithmetic, and where sites disagree →
How these programs work
- Why does a savings program have a catch?
- Because it is a marketing instrument, not a price cut. Manufacturer programs are designed to start you on a drug and to keep you refilling on schedule; the conditions are how they do that. Lilly's self-pay price for Zepbound holds only while you refill within 45 days, and Novo's $199 covers two fills. None of that is hidden — it is in the footnote under the headline.
- Why do the copay cards exclude Medicare and Medicaid?
- Federal anti-kickback rules bar manufacturers from subsidizing copays for people in federal health programs. That is why the $25 cards ask for commercial insurance. Medicare has a separate route of its own: the Medicare GLP-1 Bridge, a CMS demonstration running to 31 December 2027, under which a Part D enrollee whose prescriber's prior authorization is approved pays a $50 copay for Wegovy (pen or tablet), Foundayo or the Zepbound KwikPen.
- Do the savings cards actually work?
- Only on top of insurance that already covers most of the cost. Novo's card caps its own contribution at $100 a month, so the advertised $25 is reached when your plan has done the heavy lifting and your remaining copay is small. If your plan excludes the drug, the card takes $100 off a four-figure list price and leaves the rest with you.
halfrx is not affiliated with any manufacturer and receives nothing for listing these. Information only, not medical advice.